FDA
Decision
Approval
FDA Clears Gilead's New Single Tablet HIV Regimen Mkt cap ~$165B
Equity read-through Probabilistic High confidence MRK
MRKPotential headwind
IDVYNSO is a recently approved once-daily HIV regimen for virologically suppressed adults.